GET DAILY SIGNALSMcKesson (MCK) Advances +15% on CVS Extension and Earnings Momentum
Key Takeaways
- McKesson (MCK) climbed roughly 15% over the last 30 days, from a closing price of $866.64 on September 25, 2026 to near $996.70 in late October.
- The biggest single catalyst was an agreement in principle to extend its pharmaceutical distribution partnership with CVS Health through June 2032, which triggered a sharp one-day rally on October 1.
- A wave of analyst price-target increases — including UBS, Mizuho, Leerink Partners, and Deutsche Bank — reinforced bullish sentiment during the period.
- Strong fiscal 2027 first-quarter results, with 20% adjusted EPS growth and raised full-year guidance, provided fundamental support.
- Growth in oncology services, specialty distribution, and GLP-1 medication volumes remains central to the investment narrative.
- For additional detail, explore McKesson's Price Targets, Earnings, and Forecast pages to review analyst expectations and forward estimates.
- To see how AI-driven trading systems are positioning around this stock and others, visit the Trending AI Robots section.
Company Overview and Market Position
McKesson Corporation is one of the largest healthcare distribution and services companies in North America. Headquartered in Irving, Texas, and founded in 1833, the company distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceuticals to retail pharmacies, hospitals, health systems, and other institutions. It operates across four reportable segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions.
Investors follow MCK for its scale in drug distribution, its rapidly growing oncology and specialty platforms, and its technology-enabled services business. The company has been sharpening its portfolio toward higher-margin, higher-growth areas — including its U.S. Oncology Network, which now spans roughly 3,400 providers — while advancing the planned separation of its Medical-Surgical Solutions business under the name Wellverse. With a market capitalization above $100 billion, McKesson is a closely watched barometer of pharmaceutical supply-chain demand.
Stock Price Performance Over the Last 30 Days and Quarter
Over the last 30 days, MCK advanced from a closing price of $866.64 on September 25, 2026 to approximately $996.70 in late October — a gain of about 15%. The move was not linear; the stock pulled back into the low-$850s in late September before accelerating sharply in early October and reaching an intraday high above $1,030 on October 20, a new 52-week high. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
On a quarterly basis, the trend has been similarly constructive. Shares traded near $850 in late July and have since climbed roughly 17% over the trailing three months, reflecting steady accumulation driven by earnings momentum, a key contract extension, and improving sentiment across the healthcare distribution sector.
Key Drivers Behind the Recent 30-Day Move
The most decisive catalyst was McKesson's October 1 announcement that it had reached an agreement in principle to extend its pharmaceutical distribution relationship with CVS Health through June 2032, covering retail, mail-order, and specialty pharmacies. The news removed a major source of uncertainty around one of the company's most important customer relationships and sent the stock up roughly 5% in a single session. McKesson also reaffirmed its fiscal 2027 adjusted EPS guidance of $44.20 to $45.00 and its long-term adjusted EPS growth target of 13% to 16%.
Analyst activity amplified the move. UBS raised its price target to $1,200 from $1,080 with a Buy rating, Mizuho lifted its target to $1,020 from $905, Leerink Partners maintained a Buy with a $1,070 target, and Deutsche Bank reiterated a Buy rating. The consensus view remained favorable, with an average rating of Buy across covering analysts.
Fundamentals provided additional support. McKesson's fiscal 2027 first quarter, reported in August, showed adjusted EPS of $9.93 — up 20% year over year — on revenue of $105.38 billion, an 8% increase. The company raised its full-year EPS guidance, and GLP-1 distribution revenue reached $15 billion in the quarter, up 24% year over year.
Drivers of Performance Across the Full Quarter
The broader three-month advance reflects a combination of earnings execution and strategic repositioning. The standout performer has been the Oncology & Multispecialty segment, where revenue rose 33% to $14.2 billion and adjusted operating profit climbed 41% in the fiscal first quarter. Management expects continued double-digit growth in this business, supported by physician recruitment, geographic expansion, and AI-enabled technology.
Portfolio reshaping has also been a theme. McKesson advanced the separation of its Medical-Surgical Solutions business, secured a minority investment from Apollo Global Management, and announced the $2.25 billion acquisition of Precision Medicine Group. These moves focus the company on higher-margin specialty, oncology, and technology platforms, which investors have generally rewarded. Sector-wide strength in drug distribution peers such as Cencora and Cardinal Health contributed to a favorable backdrop.
What to Watch in the Coming Quarters
McKesson's next earnings report, covering the fiscal second quarter ended September 30, 2026, is scheduled for November 4, 2026, with consensus estimates near $10.69 in adjusted EPS on roughly $110 billion in revenue. Investors will watch for updates to full-year guidance, commentary on GLP-1 and specialty volume trends, and any impact from lower branded-drug pricing following January 2026 wholesale acquisition cost reductions.
Other factors worth monitoring include the pace of the Wellverse separation, execution of the Option Care Health infusion-therapy transaction with Clayton Dubilier & Rice, and broader regulatory and drug-pricing policy developments. Cash-flow timing and share-repurchase activity are additional checkpoints given the company's target of roughly $5 billion in buybacks for the fiscal year. From what I see, these elements will shape how the story unfolds.
Exploring AI Trading Bots for Market Context
In my own analysis, I often turn to Tickeron’s AI Trading Bots to review how automated strategies are currently positioned around MCK and similar names. The platform highlights a range of approaches, from short-term signals to longer-term models, which helps me cross-check sentiment and identify patterns without building everything from scratch. It serves as a practical complement to traditional research when evaluating healthcare distribution stocks.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
MCK in upward trend: 10-day moving average moved above 50-day moving average on October 05, 2026
The 10-day moving average for MCK crossed bullishly above the 50-day moving average on October 05, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 01, 2026. You may want to consider a long position or call options on MCK as a result. In 63 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 67%.
The Moving Average Convergence Divergence (MACD) for MCK just turned positive on October 05, 2026. Looking at past instances where MCK's MACD turned positive, the stock continued to rise in 38 of 52 cases over the following month. The odds of a continued upward trend are 73%.
MCK moved above its 50-day moving average on October 01, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.52% 3-day Advance, the price is estimated to grow further. Considering data from situations where MCK advanced for three days, in 254 of 383 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
Bearish Trend Analysis
The 10-day RSI Indicator for MCK moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 57 similar instances where the indicator moved out of overbought territory. In 24 of the 57 cases, the stock moved lower in the following days. This puts the odds of a move lower at 42%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 14 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MCK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 43%.
MCK broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for MCK entered a downward trend on October 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 8 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 75, placing this stock better than average.
The Tickeron Valuation Rating of 12 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-27.519) is normal, around the industry mean (12.169). MCK has a moderately high P/E Ratio (26.730) as compared to the industry average of (10.631). Projected Growth (PEG Ratio) (1.616) is also within normal values, averaging (2.016). Dividend Yield (0.004) settles around the average of (0.142) among similar stocks. P/S Ratio (0.265) is also within normal values, averaging (4.260).
The Tickeron Price Growth Rating for this company is 13 (best 1 - 100 worst), indicating outstanding price growth. MCK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 61 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a distributer of pharmaceuticals and provides healthcare software and health information technology services
Industry MedicalDistributors
Advertisement